Versameb AG

15.07.2020 – 15:45
Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
mehr
17.10.2019 – 16:55
Versameb raises CHF 6.4 million in Seed C round and strengthens the team
Basel (ots) - Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. The proceeds of this financing round will be used to expand ...
mehr